HRP990407A2 - Herbal extract composition and method with immune-boosting capability - Google Patents
Herbal extract composition and method with immune-boosting capability Download PDFInfo
- Publication number
- HRP990407A2 HRP990407A2 HR09/102,355A HRP990407A HRP990407A2 HR P990407 A2 HRP990407 A2 HR P990407A2 HR P990407 A HRP990407 A HR P990407A HR P990407 A2 HRP990407 A2 HR P990407A2
- Authority
- HR
- Croatia
- Prior art keywords
- extract
- composition
- hibiscus
- tea tree
- plant
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims description 131
- 238000000034 method Methods 0.000 title claims description 53
- 239000012676 herbal extract Substances 0.000 title description 22
- 239000000284 extract Substances 0.000 claims description 208
- 239000000419 plant extract Substances 0.000 claims description 91
- 235000005206 Hibiscus Nutrition 0.000 claims description 81
- 241000218033 Hibiscus Species 0.000 claims description 81
- 235000007185 Hibiscus lunariifolius Nutrition 0.000 claims description 81
- 235000009024 Ceanothus sanguineus Nutrition 0.000 claims description 75
- 240000003553 Leptospermum scoparium Species 0.000 claims description 75
- 235000015459 Lycium barbarum Nutrition 0.000 claims description 75
- 241000283707 Capra Species 0.000 claims description 59
- 210000004698 lymphocyte Anatomy 0.000 claims description 53
- 238000000338 in vitro Methods 0.000 claims description 46
- 229940109529 pomegranate extract Drugs 0.000 claims description 46
- 210000004027 cell Anatomy 0.000 claims description 39
- 235000014360 Punica granatum Nutrition 0.000 claims description 35
- 238000002360 preparation method Methods 0.000 claims description 29
- 230000024932 T cell mediated immunity Effects 0.000 claims description 27
- 230000004936 stimulating effect Effects 0.000 claims description 24
- 230000035584 blastogenesis Effects 0.000 claims description 23
- 108090000623 proteins and genes Proteins 0.000 claims description 23
- 102000004169 proteins and genes Human genes 0.000 claims description 22
- 102000004127 Cytokines Human genes 0.000 claims description 18
- 108090000695 Cytokines Proteins 0.000 claims description 18
- 239000000725 suspension Substances 0.000 claims description 17
- 230000027455 binding Effects 0.000 claims description 14
- 208000001647 Renal Insufficiency Diseases 0.000 claims description 13
- 201000006370 kidney failure Diseases 0.000 claims description 13
- 108060003951 Immunoglobulin Proteins 0.000 claims description 11
- 102000018358 immunoglobulin Human genes 0.000 claims description 11
- 230000016396 cytokine production Effects 0.000 claims description 10
- 208000032839 leukemia Diseases 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- 208000031886 HIV Infections Diseases 0.000 claims description 9
- 102000015696 Interleukins Human genes 0.000 claims description 9
- 108010063738 Interleukins Proteins 0.000 claims description 9
- 230000000638 stimulation Effects 0.000 claims description 9
- 108010050904 Interferons Proteins 0.000 claims description 8
- 102000014150 Interferons Human genes 0.000 claims description 8
- 238000009835 boiling Methods 0.000 claims description 8
- 208000037357 HIV infectious disease Diseases 0.000 claims description 7
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims description 7
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 6
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims description 6
- 230000002401 inhibitory effect Effects 0.000 claims description 3
- 229940079322 interferon Drugs 0.000 claims description 2
- 102000003390 tumor necrosis factor Human genes 0.000 claims description 2
- 239000006286 aqueous extract Substances 0.000 claims 5
- 241000219991 Lythraceae Species 0.000 claims 2
- 238000010411 cooking Methods 0.000 claims 2
- 150000004676 glycans Chemical class 0.000 claims 1
- 229920001282 polysaccharide Polymers 0.000 claims 1
- 239000005017 polysaccharide Substances 0.000 claims 1
- 244000294611 Punica granatum Species 0.000 description 33
- 238000011282 treatment Methods 0.000 description 25
- 230000009466 transformation Effects 0.000 description 19
- 241000196324 Embryophyta Species 0.000 description 15
- 241000282412 Homo Species 0.000 description 15
- 230000000694 effects Effects 0.000 description 14
- 241001465754 Metazoa Species 0.000 description 13
- 239000000126 substance Substances 0.000 description 13
- 238000002560 therapeutic procedure Methods 0.000 description 13
- 230000001965 increasing effect Effects 0.000 description 12
- 229910001220 stainless steel Inorganic materials 0.000 description 12
- 239000010935 stainless steel Substances 0.000 description 12
- 241000282414 Homo sapiens Species 0.000 description 10
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 10
- 150000001875 compounds Chemical class 0.000 description 10
- 230000028993 immune response Effects 0.000 description 10
- 108010047620 Phytohemagglutinins Proteins 0.000 description 9
- 230000001885 phytohemagglutinin Effects 0.000 description 9
- 230000003389 potentiating effect Effects 0.000 description 9
- 235000013616 tea Nutrition 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 238000001727 in vivo Methods 0.000 description 8
- 230000005764 inhibitory process Effects 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 108010074328 Interferon-gamma Proteins 0.000 description 7
- 102000003814 Interleukin-10 Human genes 0.000 description 7
- 108090000174 Interleukin-10 Proteins 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 229940072221 immunoglobulins Drugs 0.000 description 7
- 230000001506 immunosuppresive effect Effects 0.000 description 7
- 229940076144 interleukin-10 Drugs 0.000 description 7
- 229940047122 interleukins Drugs 0.000 description 7
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 6
- 244000125300 Argania sideroxylon Species 0.000 description 6
- 235000016108 Argania sideroxylon Nutrition 0.000 description 6
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
- 241000725303 Human immunodeficiency virus Species 0.000 description 6
- 239000000306 component Substances 0.000 description 6
- 230000002708 enhancing effect Effects 0.000 description 6
- 229940047124 interferons Drugs 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 230000028327 secretion Effects 0.000 description 6
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 6
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 5
- 102100037850 Interferon gamma Human genes 0.000 description 5
- 108010002350 Interleukin-2 Proteins 0.000 description 5
- 102000000588 Interleukin-2 Human genes 0.000 description 5
- 108010002616 Interleukin-5 Proteins 0.000 description 5
- 102000000743 Interleukin-5 Human genes 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 5
- 208000036142 Viral infection Diseases 0.000 description 5
- 230000000840 anti-viral effect Effects 0.000 description 5
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 5
- 235000015872 dietary supplement Nutrition 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 208000026278 immune system disease Diseases 0.000 description 5
- 229940104230 thymidine Drugs 0.000 description 5
- 230000009385 viral infection Effects 0.000 description 5
- 102000013462 Interleukin-12 Human genes 0.000 description 4
- 108010065805 Interleukin-12 Proteins 0.000 description 4
- 102000004388 Interleukin-4 Human genes 0.000 description 4
- 108090000978 Interleukin-4 Proteins 0.000 description 4
- 108090001005 Interleukin-6 Proteins 0.000 description 4
- 102000004889 Interleukin-6 Human genes 0.000 description 4
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 4
- 239000000443 aerosol Substances 0.000 description 4
- 230000036436 anti-hiv Effects 0.000 description 4
- -1 bioflavonoids Substances 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 210000000987 immune system Anatomy 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 229910052500 inorganic mineral Inorganic materials 0.000 description 4
- 239000011707 mineral Substances 0.000 description 4
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 4
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 4
- 208000023275 Autoimmune disease Diseases 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 3
- 238000012404 In vitro experiment Methods 0.000 description 3
- 229930182555 Penicillin Natural products 0.000 description 3
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 229930003268 Vitamin C Natural products 0.000 description 3
- MECHNRXZTMCUDQ-UHFFFAOYSA-N Vitamin D2 Natural products C1CCC2(C)C(C(C)C=CC(C)C(C)C)CCC2C1=CC=C1CC(O)CCC1=C MECHNRXZTMCUDQ-UHFFFAOYSA-N 0.000 description 3
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 3
- 229930003427 Vitamin E Natural products 0.000 description 3
- 229930003448 Vitamin K Natural products 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 239000003443 antiviral agent Substances 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 229960002061 ergocalciferol Drugs 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 3
- 235000008216 herbs Nutrition 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 229940049954 penicillin Drugs 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 3
- 230000005855 radiation Effects 0.000 description 3
- 229960005322 streptomycin Drugs 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 235000019154 vitamin C Nutrition 0.000 description 3
- 239000011718 vitamin C Substances 0.000 description 3
- 235000001892 vitamin D2 Nutrition 0.000 description 3
- 239000011653 vitamin D2 Substances 0.000 description 3
- MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 description 3
- 235000005282 vitamin D3 Nutrition 0.000 description 3
- 239000011647 vitamin D3 Substances 0.000 description 3
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 3
- 235000019165 vitamin E Nutrition 0.000 description 3
- 229940046009 vitamin E Drugs 0.000 description 3
- 239000011709 vitamin E Substances 0.000 description 3
- 235000019168 vitamin K Nutrition 0.000 description 3
- 239000011712 vitamin K Substances 0.000 description 3
- 150000003721 vitamin K derivatives Chemical class 0.000 description 3
- 229940021056 vitamin d3 Drugs 0.000 description 3
- 229940046010 vitamin k Drugs 0.000 description 3
- 240000000073 Achillea millefolium Species 0.000 description 2
- 235000007754 Achillea millefolium Nutrition 0.000 description 2
- 206010000830 Acute leukaemia Diseases 0.000 description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 2
- 241000157855 Cinchona Species 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 239000012981 Hank's balanced salt solution Substances 0.000 description 2
- 241000701806 Human papillomavirus Species 0.000 description 2
- 241001632576 Hyacinthus Species 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 102000008070 Interferon-gamma Human genes 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 240000000982 Malva neglecta Species 0.000 description 2
- 235000000060 Malva neglecta Nutrition 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 244000269722 Thea sinensis Species 0.000 description 2
- 235000006468 Thea sinensis Nutrition 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 210000000601 blood cell Anatomy 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000001882 diuretic effect Effects 0.000 description 2
- 235000014134 echinacea Nutrition 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 229940044627 gamma-interferon Drugs 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 230000007721 medicinal effect Effects 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 229960005181 morphine Drugs 0.000 description 2
- 235000008935 nutritious Nutrition 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 239000002831 pharmacologic agent Substances 0.000 description 2
- 239000011574 phosphorus Substances 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 230000016412 positive regulation of cytokine production Effects 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 238000005057 refrigeration Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- 235000001258 Cinchona calisaya Nutrition 0.000 description 1
- 241000709687 Coxsackievirus Species 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 206010011968 Decreased immune responsiveness Diseases 0.000 description 1
- 244000133098 Echinacea angustifolia Species 0.000 description 1
- 240000004530 Echinacea purpurea Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 240000001238 Gaultheria procumbens Species 0.000 description 1
- 235000007297 Gaultheria procumbens Nutrition 0.000 description 1
- 108010039334 HIV Envelope Protein gp120 Proteins 0.000 description 1
- 208000007514 Herpes zoster Diseases 0.000 description 1
- 101001002709 Homo sapiens Interleukin-4 Proteins 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 102000003996 Interferon-beta Human genes 0.000 description 1
- 108090000467 Interferon-beta Proteins 0.000 description 1
- 102000008072 Lymphokines Human genes 0.000 description 1
- 108010074338 Lymphokines Proteins 0.000 description 1
- 108010050619 Monokines Proteins 0.000 description 1
- 102000013967 Monokines Human genes 0.000 description 1
- 229920000715 Mucilage Polymers 0.000 description 1
- 208000001388 Opportunistic Infections Diseases 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 240000001090 Papaver somniferum Species 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 241000899950 Salix glauca Species 0.000 description 1
- 241000220286 Sedum Species 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 241000015728 Taxus canadensis Species 0.000 description 1
- 102000009618 Transforming Growth Factors Human genes 0.000 description 1
- 108010009583 Transforming Growth Factors Proteins 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 244000274883 Urtica dioica Species 0.000 description 1
- 235000009108 Urtica dioica Nutrition 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 241000711975 Vesicular stomatitis virus Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 238000012863 analytical testing Methods 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229940093797 bioflavonoids Drugs 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 239000003560 cancer drug Substances 0.000 description 1
- 210000004970 cd4 cell Anatomy 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 1
- 229960004126 codeine Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 235000021321 essential mineral Nutrition 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 239000000576 food coloring agent Substances 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 235000020710 ginseng extract Nutrition 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 102000055229 human IL4 Human genes 0.000 description 1
- 235000006486 human diet Nutrition 0.000 description 1
- 210000005104 human peripheral blood lymphocyte Anatomy 0.000 description 1
- 239000010903 husk Substances 0.000 description 1
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000013383 initial experiment Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000008611 intercellular interaction Effects 0.000 description 1
- 230000010262 intracellular communication Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 1
- GGGDNPWHMNJRFN-UHFFFAOYSA-N metrizoic acid Chemical compound CC(=O)N(C)C1=C(I)C(NC(C)=O)=C(I)C(C(O)=O)=C1I GGGDNPWHMNJRFN-UHFFFAOYSA-N 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 229940124641 pain reliever Drugs 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 235000006502 papoula Nutrition 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 229960000948 quinine Drugs 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000004565 tumor cell growth Effects 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- 230000024058 virion binding Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/82—Theaceae (Tea family), e.g. camellia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/888—Araceae (Arum family), e.g. caladium, calla lily or skunk cabbage
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/102,355 US6030622A (en) | 1998-06-23 | 1998-06-23 | Herbal extract composition and method with immune-boosting capability |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP990407A2 true HRP990407A2 (en) | 2000-04-30 |
Family
ID=22289416
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR09/102,355A HRP990407A2 (en) | 1998-06-23 | 1999-12-23 | Herbal extract composition and method with immune-boosting capability |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US6030622A (zh) |
| EP (1) | EP1032409A4 (zh) |
| JP (1) | JP2002518454A (zh) |
| KR (1) | KR20010020586A (zh) |
| CN (1) | CN1272792A (zh) |
| AP (1) | AP2000001727A0 (zh) |
| AU (1) | AU773546B2 (zh) |
| BG (1) | BG63865B1 (zh) |
| BR (1) | BR9906480A (zh) |
| CA (1) | CA2294075A1 (zh) |
| EA (1) | EA003750B1 (zh) |
| EE (1) | EE200000053A (zh) |
| HR (1) | HRP990407A2 (zh) |
| ID (1) | ID25661A (zh) |
| IL (1) | IL133441A0 (zh) |
| NO (1) | NO995718L (zh) |
| NZ (1) | NZ501405A (zh) |
| OA (1) | OA11396A (zh) |
| PL (1) | PL338263A1 (zh) |
| SK (1) | SK169199A3 (zh) |
| TR (1) | TR200000501T1 (zh) |
| WO (1) | WO1999066941A1 (zh) |
| ZA (1) | ZA997713B (zh) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8603546B2 (en) * | 1999-01-11 | 2013-12-10 | Herbaceuticals Inc. | Herbal supplement for increased muscle strength and endurance for athletes |
| US6387418B1 (en) * | 1999-04-19 | 2002-05-14 | Stewart And Lynda Resnick Revocable Trust | Pomegranate extracts and methods of using thereof |
| WO2000056177A2 (en) * | 1999-03-22 | 2000-09-28 | Stewart And Lynda Resnick Revocable Trust | Pomegranate extracts and methods of using thereof |
| US7727563B2 (en) * | 1999-04-19 | 2010-06-01 | Pom Wonderful, Llc | Methods of using pomegranate extracts for treating diabetes related atherosclerotic complications in humans |
| US6641850B1 (en) | 1999-04-19 | 2003-11-04 | Stewart And Lynda Resnick Revocable Trust | Methods of using pomegranate extracts for causing regression in lesions due to arteriosclerosis in humans |
| US8372454B2 (en) | 1999-04-19 | 2013-02-12 | Pom Wonderful Llc | Methods of making pomegranate compounds for the treatment of erectile dysfunction |
| US6800292B1 (en) * | 1999-04-22 | 2004-10-05 | Howard Murad | Pomegranate fruit extract compositions for treating dermatological disorders |
| US6630163B1 (en) * | 1999-04-22 | 2003-10-07 | Howard Murad | Method of treating dermatological disorders with fruit extracts |
| US20020197341A1 (en) * | 1999-11-29 | 2002-12-26 | Rimonest Ltd. | Physiologically synergistic mixtures of pomegranate extracts and methods of use thereof |
| WO2002008258A2 (en) * | 2000-07-21 | 2002-01-31 | Millennium Pharmaceuticals, Inc. | 65494, a human g-protein-coupled receptor family member and uses thereof |
| US20030004211A1 (en) * | 2001-05-25 | 2003-01-02 | Frank Corsini | Carbohydrate modifying agent and drinks containing the modifying agent |
| US20030017219A1 (en) * | 2001-05-25 | 2003-01-23 | Frank Corsini | Carbohydrate modifying agent and drinks containing the modifying agent |
| MXPA04006106A (es) * | 2001-12-21 | 2004-11-01 | Eastern Virginia Med School | Metodo para analizar los efectos de agentes medicinales. |
| KR20020041348A (ko) * | 2002-02-28 | 2002-06-01 | 이성희 | 면역기능을 강화시킨 바이오 홀몬파워 제조 |
| US20040013749A1 (en) * | 2002-07-22 | 2004-01-22 | Young D. Gary | Antioxidant and immune boosting composition and methods of using |
| EP1734946B1 (en) * | 2004-01-20 | 2012-06-27 | Nutrition Therapeutics, Inc. | Punicic acid for use to enhance immune response and treating inflammatory bowel disease |
| WO2005072722A2 (en) * | 2004-01-20 | 2005-08-11 | Nutrition Therapeutics, Inc. | Method of using punicic acid to enhance immune response and prevent metabolic disorders |
| US7507424B2 (en) * | 2004-04-26 | 2009-03-24 | Mmi Corporation | Natural immunostimulant compositions, methods for obtaining the same and pharmaceutical formulations thereof |
| US20060062866A1 (en) * | 2004-09-21 | 2006-03-23 | New York Blood Center, Inc. | Starch-pomegranate juice complex as an HIV entry inhibitor and topical microbicide |
| US20060189543A1 (en) * | 2005-02-23 | 2006-08-24 | Rosenbloom Richard A | Compositions and methods for the treatment of leukemia |
| US9028882B2 (en) | 2005-05-02 | 2015-05-12 | 4Life Patents, Llc | Nutraceutical gels |
| MX2007013850A (es) * | 2005-05-02 | 2008-04-09 | 4Life Patents Llc | Preparaciones de factor de transferencia y metodos asociados. |
| US20080057143A1 (en) * | 2006-06-01 | 2008-03-06 | Mohammad Madjid | Method of using composition comprising pomegranate extracts against influenza |
| US7303772B2 (en) * | 2005-11-10 | 2007-12-04 | Olalde Rangel Jose Angel | Synergistic phytoceutical compositions |
| US20080031979A1 (en) * | 2006-08-04 | 2008-02-07 | Claude Saliou | Use of extracts for the treatment of viral disorders |
| US7811554B2 (en) | 2007-01-19 | 2010-10-12 | Flavio Lozano | Horse liniment |
| US20090169654A1 (en) * | 2007-12-14 | 2009-07-02 | Conopco, Inc. D/B/A Unilever | Tea composition and process for the manufacture thereof |
| US20090175964A1 (en) * | 2007-12-14 | 2009-07-09 | Conopco, Inc. D/B/A Unilever | Composition for enhancing immunity |
| US8257769B2 (en) * | 2007-12-14 | 2012-09-04 | Conopco, Inc. | Process for recovering volatile tea compounds |
| US8263140B1 (en) | 2008-04-16 | 2012-09-11 | Pom Wonderful, Llc | Pomegranate based skin protectant and topical application |
| PT2310023T (pt) * | 2008-07-31 | 2016-11-22 | Sigma Tau Ind Farmaceuti | Composição compreendendo extrato de chá verde e extrato de romã para utilização na prevenção ou redução da progressão de cancro prostático |
| RU2414210C1 (ru) * | 2009-12-28 | 2011-03-20 | Общество С Ограниченной Ответственностью "Сплат-Косметика" (Ооо "Сплат-Косметика") | Средство для удаления табачных смол и композиции на его основе |
| US8039025B1 (en) | 2010-10-15 | 2011-10-18 | Life Plus, LLC | Methods and dosage forms for the treatment of human cancers |
| US20150140125A1 (en) * | 2013-11-19 | 2015-05-21 | Life Plus, LLC | Synergistic cancer therapy drug combinations |
| IT202100010409A1 (it) * | 2021-04-23 | 2022-10-23 | Esserre Pharma Srl | Composizione comprendente un fitocomplesso da melograno e suoi usi |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4104373A (en) * | 1969-06-20 | 1978-08-01 | Richard Sichert | Therapeutical composition |
| JPS56147719A (en) * | 1980-04-18 | 1981-11-16 | Meiji Seika Kaisha Ltd | Production of dried ginseng |
| US4671959A (en) * | 1984-11-14 | 1987-06-09 | Yale University | Method of causing the reduction of physiological and/or subjective reactivity to stress in humans being subjected to stress conditions |
| US4886665A (en) * | 1987-03-11 | 1989-12-12 | Arcopharma Ltd. | Compositions of oats and nettle extracts to be used as a food additive or pharmaceutical preparation in human health care |
| JPH02286620A (ja) * | 1989-04-27 | 1990-11-26 | Riide Chem Kk | 抗高脂血症用剤 |
| WO1991013627A1 (en) * | 1990-03-14 | 1991-09-19 | The Board Of Regents, The University Of Texas System | Tripterygium wilfordii hook f extracts and components thereof for immunosuppression |
| US5178865A (en) * | 1990-06-19 | 1993-01-12 | Cedars-Sinai Medical Center | Chinese herbal extracts in the treatment of hiv related disease in vitro |
| US5407675A (en) * | 1990-08-10 | 1995-04-18 | Etemad-Moghadam; Parviz | Method and composition for use on the scalp and eyebrow region of a subject |
| US5064675A (en) * | 1991-03-01 | 1991-11-12 | Scandinavian Natural Resources Development Hb | Herbal extract composition |
| JPH0840B2 (ja) * | 1991-10-31 | 1996-01-10 | 株式会社東洋発酵 | 活性酸素抑制組成物及びその製造方法並びに血圧抑制剤 |
| RU2032418C1 (ru) * | 1993-05-19 | 1995-04-10 | Игорь Электринович Острейковский | Тонизирующее средство для улучшения самочувствия в условиях повышенной температуры окружающей среды |
| EP0667162A1 (de) * | 1994-02-11 | 1995-08-16 | Rudolf Brunner | Pflanzliches Heilmittel und Verfahren zu dessen Herstellung |
| WO1995022254A1 (en) * | 1994-02-17 | 1995-08-24 | Merck Patent Gmbh | Antiviral or antifungal composition and method |
| JP3542357B2 (ja) * | 1994-08-08 | 2004-07-14 | ザ、プロクター、エンド、ギャンブル、カンパニー | 茶及びフルーツジュースを含有した色安定性組成物 |
| JPH0987188A (ja) * | 1995-09-19 | 1997-03-31 | Ichimaru Pharcos Co Ltd | 皮膚外用剤及び浴用剤 |
| JP3213557B2 (ja) * | 1996-11-18 | 2001-10-02 | 三井農林株式会社 | 茶カテキンを有効成分として含有する尖圭コンジローマ治療剤 |
-
1998
- 1998-06-23 US US09/102,355 patent/US6030622A/en not_active Expired - Fee Related
-
1999
- 1999-06-19 PL PL99338263A patent/PL338263A1/xx unknown
- 1999-06-19 IL IL13344199A patent/IL133441A0/xx unknown
- 1999-06-19 BR BR9906480-4A patent/BR9906480A/pt not_active IP Right Cessation
- 1999-06-19 CN CN99800880A patent/CN1272792A/zh active Pending
- 1999-06-19 AU AU47018/99A patent/AU773546B2/en not_active Ceased
- 1999-06-19 WO PCT/US1999/013949 patent/WO1999066941A1/en not_active Application Discontinuation
- 1999-06-19 EE EEP200000053A patent/EE200000053A/xx unknown
- 1999-06-19 CA CA002294075A patent/CA2294075A1/en not_active Abandoned
- 1999-06-19 TR TR2000/00501T patent/TR200000501T1/xx unknown
- 1999-06-19 NZ NZ501405A patent/NZ501405A/en unknown
- 1999-06-19 EP EP99930484A patent/EP1032409A4/en not_active Withdrawn
- 1999-06-19 JP JP2000555627A patent/JP2002518454A/ja active Pending
- 1999-06-19 SK SK1691-99A patent/SK169199A3/sk unknown
- 1999-06-19 ID IDW991710A patent/ID25661A/id unknown
- 1999-06-19 KR KR1019997012550A patent/KR20010020586A/ko not_active Application Discontinuation
- 1999-06-19 EA EA200000236A patent/EA003750B1/ru not_active IP Right Cessation
- 1999-11-22 NO NO995718A patent/NO995718L/no not_active Application Discontinuation
- 1999-12-08 BG BG103967A patent/BG63865B1/bg unknown
- 1999-12-15 ZA ZA9907713A patent/ZA997713B/xx unknown
- 1999-12-23 HR HR09/102,355A patent/HRP990407A2/hr not_active Application Discontinuation
-
2000
- 2000-01-07 AP APAP/P/2000/001727A patent/AP2000001727A0/en unknown
- 2000-02-04 OA OA1200000027A patent/OA11396A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AP2000001727A0 (en) | 2000-12-19 |
| TR200000501T1 (tr) | 2000-11-21 |
| PL338263A1 (en) | 2000-10-09 |
| NZ501405A (en) | 2002-05-31 |
| NO995718D0 (no) | 1999-11-22 |
| OA11396A (en) | 2004-04-08 |
| BG63865B1 (bg) | 2003-04-30 |
| AU773546B2 (en) | 2004-05-27 |
| NO995718L (no) | 2000-01-18 |
| CN1272792A (zh) | 2000-11-08 |
| EA200000236A1 (ru) | 2000-08-28 |
| ZA997713B (en) | 2000-08-01 |
| EP1032409A1 (en) | 2000-09-06 |
| EA003750B1 (ru) | 2003-08-28 |
| BG103967A (en) | 2000-10-31 |
| ID25661A (id) | 2000-10-19 |
| EP1032409A4 (en) | 2004-01-21 |
| WO1999066941A1 (en) | 1999-12-29 |
| JP2002518454A (ja) | 2002-06-25 |
| EE200000053A (et) | 2000-10-16 |
| KR20010020586A (ko) | 2001-03-15 |
| BR9906480A (pt) | 2000-09-19 |
| CA2294075A1 (en) | 1999-12-29 |
| SK169199A3 (en) | 2000-06-12 |
| AU4701899A (en) | 2000-01-10 |
| IL133441A0 (en) | 2001-04-30 |
| US6030622A (en) | 2000-02-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP990407A2 (en) | Herbal extract composition and method with immune-boosting capability | |
| CN104012807B (zh) | 一种畜禽用抗病毒复合维生素预混合饲料制剂和制备方法及其应用 | |
| CN103621869B (zh) | 一种大鲵低聚糖肽保健品 | |
| US20060159725A1 (en) | Herbal compositions | |
| WO2003068145A2 (en) | Herbal immune system stimulant | |
| CN103653009A (zh) | 一种美容养颜药膳乌鸡 | |
| CN103142916B (zh) | 一种预防和治疗老年性痴呆病的药物 | |
| CN108813610A (zh) | 一种用于提高免疫力的雪莲组合物及其应用 | |
| CN110477209A (zh) | 一种增强肉鸡免疫力的肉鸡饲料 | |
| CN101474272A (zh) | 动物用复方中草药免疫增强剂及其制备方法 | |
| JPH11158077A (ja) | ストレス軽減効果のある組成物 | |
| WO2018228431A1 (zh) | 升麻三萜皂苷类提取物、黄肉楠碱、脱氧升麻烃的用途 | |
| Egba et al. | Oral administration of methanol extract of Gongronema latifolium (utazi) Up-Regulates cytokine expression and influences the immune system in wistar albino rats | |
| WO2006008761A2 (en) | Anti retroviral herbal formulation | |
| MXPA99012105A (es) | Composicion de extractos herbales y metodo con capacidad de refuerzo inmune | |
| JP4245291B2 (ja) | 生理活性組成物及びその製造方法 | |
| CN107233490A (zh) | 一种益气养阴美容养颜的玛咖组合物 | |
| CN108245608A (zh) | 一种有效抑制肿瘤的中草药及其制备方法 | |
| CZ438499A3 (cs) | Komposice rostlinného extraktu a způsob se schopností posilovat imunitu | |
| CN109528827B (zh) | 一种活血祛瘀、降血脂的药物组合物、制剂及其制备方法 | |
| CN108452047B (zh) | 延缓衰老抑制肿瘤细胞生长改善心脑血管微循环的组合物 | |
| CN113975363A (zh) | 一种增强免疫力的粉雏菊组合物 | |
| CN109045103A (zh) | 一种复合甘草素及其制备方法和用途 | |
| KR20230046094A (ko) | 전통 중약 조성물 및 이의 제조방법 | |
| CN117357627A (zh) | 一种提高家禽机体免疫力的复合药物及其制备方法和应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A1OB | Publication of a patent application | ||
| AIPI | Request for the grant of a patent on the basis of a substantive examination of a patent application | ||
| ODBI | Application refused |